NED Biosystems strengthened its Board of Directors with the appointment of a highly accomplished physician-scientist and biotechnology executive, José Trevejo, MD, PhD. The appointment of Dr. Trevejo, who has led organizations in the development of high impact medicines spanning multiple therapeutic areas, will bring a key life sciences expertise to the Board. His current work in developing transformative therapies using nature’s chemistry is also well aligned with NED’s own incorporation of natural substances into systems-based approaches that promise to transform how cancer patients are treated globally.
Dr. Trevejo is currently the Chief Medical Officer and Head of Clinical Pipeline Strategy at Enveda Biosciences which is developing new medicines from natural products utilizing AI. Prior to Enveda he was the CMO of Tarsus Pharma where he helped lead the FDA approval and successful launch of a novel category-creating ophthalmology drug. Dr. Trevejo also served as CDO for Rocket Pharmaceuticals and CEO of the non-viral gene therapy company SmartPharm, which was acquired in 2020. Prior to SmartPharm, Dr. Trevejo held increasing roles of responsibility at Ironwood, Genentech and Vertex Pharmaceuticals. Dr. Trevejo received his M.D. and Ph.D. at the Cornell-Rockefeller-Sloan Kettering Tri-Institutional M.D./Ph.D. Program and completed his residency and specialty training at Harvard Medical School affiliates BWH and BIDMC.
Dr. Trevejo will support NED’s mission as a Delaware Public Benefit Corporation to reach patients across the globe who currently lack access to care.
About NED Biosystems:
Based in Cambridge, Massachusetts, NED Biosystems is a clinical-stage biotech company focused on patients and their families. NED’s mission is to enable patients to achieve and sustain No Evidence of Disease. The Company’s novel platform has designed treatments to address large unmet needs for cancer and infectious disease patients. The intent is to achieve what today’s HIV treatments have: to transform what may be a death sentence diagnosis to No Disease, or reliably managed disease with quality of life.
NED’s novel platform pioneers a data-driven methodology. By simultaneously and redundantly affecting the processes driving disease, well-established by decades of research, treatments are designed to arrest disease progression and normalize disease-related imbalances. Deploying safe, evidenced-based agents lacking customary toxicity and side effects, NED’s treatments are comprehensive unlike today’s narrowly targeted therapies.
NED is a Delaware Public Benefit Company seeking to make its therapies accessible in both developed and developing countries.
For more information, visit https://nedbiosystems.com/.
For additional information regarding this press release, please contact info@nedbiosystems.com.
PHOTO links for media:
https://nedbiosystems.com/wp-content/uploads/2020/07/Trevejo-Jose_square-low-res-e1733927422620.jpg
Caption: José Trevejo, MD, PhD, NED Biosystems’ New Director to the Board.
NED Biosystems has added key finance expertise to its Board of Directors through the recent appointment of John Thomas, CPA. Mr. Thomas brings to the board almost 40 years of executive experience in corporate finance. He has guided life sciences companies through the full spectrum of development from the formation of the company and the initial fund-raising efforts to the sale transaction or initial public offering. This wealth of experience will be invaluable to NED as it moves through its upcoming financing round and into clinical development.
NED congratulates our Board Director Carolina Alarco on receiving LabCentral Ignite’s inaugural Ted W. Love Award for Individual Impact on Life Sciences Diversity, Equity, & Inclusion at the first annual bioDiversity Summit Awards Dinner on September 28, 2022.
Ms. Forlenza, a NY State Licensed CPA, brings over 35 years of experience in corporate finance to the Board. She has a proven track record leading privately and publicly held companies from inception to growth and profitability. Since founding LC Forlenza Advisory Services in 1987, she has advised over 250 long-tenured clients across the globe on a wide range of financial matters including tax and audit strategy, forensic accounting, mergers, and reporting. Throughout the 1980s and early 1990s, Ms. Forlenza led audit and tax relationships with international audit firms on behalf of global brokerage firms Bierbaum-Martin Inc and International Exchange Partners. She led operations for these firms in London, Dusseldorf, and New York. Ms. Forlenza has held numerous board positions advising companies on audit and tax-related matters and currently serves as Chair of the Audit Committee for the Board of Innodata Inc. She holds a Certificate in Forensic Accounting from NYU and BBA in Accounting from Iona College where she was the first and only female accounting major in her graduating class, and she has completed Executive Training Programs at Harvard Business School and The Wharton School.
Dr. El-Bardeesy is Associate Professor of Medicine at the Harvard Medical School and a leading authority on the causes of cancer. Dr. El-Bardeesy also serves as the Cholangiocarcinoma Foundation Scientific and Medical Advisory Board Co-Chair. Dr. El-Bardeesy additionally is Assistant Professor at Massachusetts General Hospital Cancer Center and is an instructor at the Dana-Farber Cancer Institute. Dr. El-Bardeesy is widely published on the molecular and cellular mechanisms that drive certain types of cancer.
Dr. Kurzrock is Professor of Medicine and Associate Director for Clinical Sciences at the University of San Diego Moore Cancer Center. She leads the Center’s clinical trial programs and heads its recently established Center for Personalized Cancer Therapy. Dr. Kurzrock’s distinguished track record includes leading one of the largest phase one clinical trial programs at the University of Texas MD Anderson Cancer Center, where she spearheaded an innovative approach that utilized advanced molecular technologies to match patients with targeted cancer treatment that optimized the possibility for response.